Post-induction residual leukemia in childhood acute lymphoblastic leukemia quantified by PCR correlates with in vitro prednisolone resistance

[1]  G. Gustafsson,et al.  Improving outcome through two decades in childhood ALL in the Nordic countries: the impact of high-dose methotrexate in the reduction of CNS irradiation , 2000, Leukemia.

[2]  K. Schmiegelow,et al.  Competitive PCR for quantification of minimal residual disease in acute lymphoblastic leukaemia. , 2000, Journal of immunological methods.

[3]  M. Kami,et al.  Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood , 1998, The Lancet.

[4]  W. Hop,et al.  Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood , 1998, The Lancet.

[5]  G. Gustafsson,et al.  Intensified treatment of acute childhood lymphoblastic leukaemia has improved prognosis, especially in non‐high‐risk patients: the Nordic experience of 2648 patients diagnosed between 1981 and 1996 , 1998, Acta paediatrica.

[6]  H. Cavé,et al.  Clinical Significance of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia , 1998 .

[7]  R. Pieters,et al.  Prednisolone resistance in childhood acute lymphoblastic leukemia: vitro-vivo correlations and cross-resistance to other drugs. , 1998, Blood.

[8]  Elaine Coustan-Smith,et al.  Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia , 1998, The Lancet.

[9]  H. Sather,et al.  Early response to therapy and outcome in childhood acute lymphoblastic leukemia , 1997, Cancer.

[10]  R. Pieters,et al.  In Vitro Cellular Drug Resistance and Prognosis in Newly Diagnosed Childhood Acute Lymphoblastic Leukemia , 1997 .

[11]  S. Richards,et al.  Clearance of marrow infiltration after 1 week of therapy for childhood lymphoblastic leukaemia: clinical importance and the effect of daunorubicin , 1997, British journal of haematology.

[12]  T. Hongo,et al.  In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia. , 1997, Blood.

[13]  R. Pieters,et al.  Mononuclear cells contaminating acute lymphoblastic leukaemic samples tested for cellular drug resistance using the methyl-thiazol-tetrazolium assay. , 1994, British Journal of Cancer.

[14]  W. Hiddemann,et al.  Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. , 1994, Blood.

[15]  H. Cavé,et al.  Prospective monitoring and quantitation of residual blasts in childhood acute lymphoblastic leukemia by polymerase chain reaction study of delta and gamma T-cell receptor genes. , 1994, Blood.

[16]  A. Morley,et al.  Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction , 1994, The Lancet.

[17]  M. Hancock,et al.  Treatment of acute lymphoblastic leukemia : 30 years' experience at St. Jude Children's Research Hospital , 1993 .

[18]  J. Silber,et al.  Residual disease at the end of induction therapy as a predictor of relapse during therapy in childhood B-lineage acute lymphoblastic leukemia. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  R. Pieters,et al.  In vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukaemic cells from bone marrow and peripheral blood. , 1991, British Journal of Cancer.

[20]  R. Pieters,et al.  In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions , 1990 .

[21]  H. Sather,et al.  Early response to induction therapy as a predictor of disease-free survival and late recurrence of childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  R. Pieters,et al.  Comparison of the rapid automated MTT-assay with a dye exclusion assay for chemosensitivity testing in childhood leukaemia. , 1989, British Journal of Cancer.

[23]  R. Pieters,et al.  Adaptation of the rapid automated tetrazolium dye based (MTT) assay for chemosensitivity testing in childhood leukemia. , 1988, Cancer letters.

[24]  E. Gehan,et al.  Interrupted vs. continued maintenance therapy in childhood acute leukemia , 1975, Cancer.

[25]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[26]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[27]  R. Pieters,et al.  Everything you always wanted to know about cellular drug resistance in childhood acute lymphoblastic leukemia. , 1997, Critical reviews in oncology/hematology.

[28]  H. Sather,et al.  Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features. , 1990, Medical and pediatric oncology.

[29]  Ó. Jónsson,et al.  Detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin hypervariable region specific oligonucleotide probes. , 1990, Blood.

[30]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .

[31]  G. Paolucci,et al.  [Treatment of acute lymphoblastic leukemia]. , 1971, Minerva pediatrica.

[32]  Bernice W. Polemis.  Nonparametric Statistics for the Behavioral Sciences , 1959 .